| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3762ef05a2c89457d068edd9e27e3ff |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
2006-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1230c42925e1de552f0b084a217e27b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48a5ae6bdb9a1b1851e7453938aa555c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d2a574cce9a5a0c010396058bc14c13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c091b22deaf6d26973999c00cc4cfc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6f1a692cf44651b3200018a1f1dd389
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9c656b461caaad98b0bb383f92884e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b601164cd166674a9c838c0361c6f516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97df13ecd8300a348a3a6f128590f86f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_822252685bd95d780f78a3d12641e68d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a753644ad3dd876bf5e90a0ff6ad0db1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afc78bc1d5a4b4bdb812552e164f0414
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10d4474d3d6a09dc059cf731607f4730
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62f1b5bfb453e25ce325da39a171b575 |
| publicationDate |
2008-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101204391-A |
| titleOfInvention |
Isoflavone compound curing atherosclerosis through strengthening reverse cholesterol transport mechanism and composite thereof |
| abstract |
The invention relates to the application of isoflavones red clover (form 1) and genistein (form 2). The invention is utilized for the preparation of medicine through strengthening the reverse cholesterol transport processed treatment and/or preventing the atherosclerosis. The medicine of strengthing the reverse cholesterol transport processed treatment and/or preventing the atherosclerosis comprises the medicine presented the liveness through the up-regulation of the high density lipoprotein receptor CLA-1/SR-BI and the ATP cassette antigen ABCA1. The invention also relates to the drug composition of strengthening the reverse cholesterol transport processed treatment and/or preventing the atherosclerosis, the active constituents efficient chosen from the isoflavones red clover (form 1) and genistein (form 2) provided on the drug composition and optional carrier which is able to be adopted by the pharmacy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102992983-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102391258-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108721609-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108721609-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102391258-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102992983-B |
| priorityDate |
2006-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |